Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
26 October 2020 - 11:00PM
Business Wire
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it
is has been named one of the Most Innovative Companies in Chicago
by Crain’s Chicago Business. Crain’s compiles the list based on a
review by independent intellectual property valuation firm, Ocean
Tomo, which evaluates the patents produced each year by
Chicago-area companies.
Horizon made this year’s list based on its work with its
medicine used to treat urea cycle disorders (UCD), a rare genetic
disorder that affects approximately 1 in 35,000 live births in the
United States.
“At Horizon, innovation is more than a buzz word – it’s the
difference between someone having a treatment for their rare or
rheumatic disease or living with the day-to-day complications of
chronic illness,” said Tim Walbert, chairman, president and chief
executive officer, Horizon. “Especially during this challenging
time, we are honored to be recognized by Crain’s as a company
leading the way in bringing critical medicines to those in need. We
remain committed to working with patients, physicians, academic
centers and other companies to collaboratively address the most
pressing needs facing patients.”
About Crain’s Chicago Business
Crain’s Chicago Business is the top source of news, analysis and
information on business in metropolitan Chicago for decision-makers
in the private and public sectors. Crain's publishes a weekly
business magazine, providing deeper analysis, commentary, special
reports and features. Crain's also produces databases, live events
and sponsored content, all with the aim of deepening readers'
understanding of local business. Crain’s Chicago Business is the
leading source of information on Chicago’s economy, the companies,
industries and institutions that operate here and the entrepreneurs
and innovators who drive the city’s growth.
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com and follow us on Twitter,
LinkedIn, Instagram and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005316/en/
U.S. Media Contact: Geoff Curtis Executive Vice
President, Corporate Affairs & Chief Communications Officer
media@horizontherapeutics.com
Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024